含有轴向羧酸盐的基于卡铂的铂 ( IV ) 前药相对难以还原释放活性铂 ( II ) 物质并杀死癌细胞。为了促进活化过程,二吡咯亚甲基硼 (BODIPY) 配体被用作轴向位置的光吸收剂,以光活化卡铂基铂 ( IV ) 配合物。然而,轴向配体对铂中心光活化速率和随后的生物活性的影响仍然未知。在本研究中,我们报道了一系列含有不同长度的BODIPY轴向配体的卡铂基光活化铂( IV )前药的设计和合成。所得的 BODIPY 共轭铂 ( IV ) 前药OH2C–OH8C在相反的轴向位置带有羟基配体,在黑暗中比相应的含有乙酰基配体的前药AC2C–AC8C稳定性稍差。前药OH3C-OH8C在照射下可在8分钟内光活化,前药AC3C-AC8C的光活化速率进一步提高,仅需20秒。此外,前药AC3C ,其中BODIPY光吸收剂和铂中心之间的连接体具有适当的长度,在乙酰化前药AC2C-AC8C中光活化最快。高细胞
Studies on the Secondary Structure of Bradykinin in Aqueous Solution. Syntheses, Circular Dichroism Spectra, and Biological Activities of Bradykinin Analogs Containing 5-Aminovaleric Acid Residue
of Arg1 and the carboxyl group of Arg9, was proposed for the secondarystructure of bradykinin in aqueous solution. The biological activities of these analogs depend on the presence of both Phe residues at positions 5 and 8, and Arg residues at positions 1 and 9. No correlation between the biological activities and the secondarystructure could be found.